Ipsen: 8% increase in Core EPS in 2020
(CercleFinance.com) - For 2020 Ipsen has published Core EPS that is up 8.
4% at 7.31 euros, with a core operating margin of 32% (+1.6 point) for sales that are up 0.6% to 2.59 billion euros (+3% at constant exchange rates), driven by specialty medicine.
In addition, the pharmaceutical company boasts a solid financial structure and will propose a dividend of one euro per share to shareholders for FY 2020, unchanged from the previous year.
In 2021 Ipsen anticipates sales growth of over 4% at constant exchange rates and an operating margin of over 30% for 2021. It will prioritise the execution of its new strategy.
Copyright (c) 2021 CercleFinance.com. All rights reserved.
4% at 7.31 euros, with a core operating margin of 32% (+1.6 point) for sales that are up 0.6% to 2.59 billion euros (+3% at constant exchange rates), driven by specialty medicine.
In addition, the pharmaceutical company boasts a solid financial structure and will propose a dividend of one euro per share to shareholders for FY 2020, unchanged from the previous year.
In 2021 Ipsen anticipates sales growth of over 4% at constant exchange rates and an operating margin of over 30% for 2021. It will prioritise the execution of its new strategy.
Copyright (c) 2021 CercleFinance.com. All rights reserved.